168 related articles for article (PubMed ID: 38092415)
1. [Acute hepatic porphyrias: pathophysiology and pathogenesis of acute attacks].
Yasuda M
Rinsho Shinkeigaku; 2024 Jan; 64(1):8-16. PubMed ID: 38092415
[TBL] [Abstract][Full Text] [Related]
2. RNA interference therapy in acute hepatic porphyrias.
Yasuda M; Keel S; Balwani M
Blood; 2023 Nov; 142(19):1589-1599. PubMed ID: 37027823
[TBL] [Abstract][Full Text] [Related]
3. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Sardh E; Harper P
J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
[TBL] [Abstract][Full Text] [Related]
4. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Wang B; Bonkovsky HL; Lim JK; Balwani M
Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).
Bonkovsky HL; Dixon N; Rudnick S
Mol Genet Metab; 2019 Nov; 128(3):213-218. PubMed ID: 30987916
[TBL] [Abstract][Full Text] [Related]
6. Case-based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management.
Balwani M; Keel S; Meissner P; Sonderup M; Stein P; Yasuda M
Liver Int; 2024 Apr; ():. PubMed ID: 38618923
[TBL] [Abstract][Full Text] [Related]
7. Givosiran for the treatment of acute hepatic porphyria.
Ricci A; Ventura P
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
[TBL] [Abstract][Full Text] [Related]
8. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.
Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P
Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955
[TBL] [Abstract][Full Text] [Related]
9. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study.
Naik H; Stoecker M; Sanderson SC; Balwani M; Desnick RJ
Mol Genet Metab; 2016 Nov; 119(3):278-283. PubMed ID: 27595545
[TBL] [Abstract][Full Text] [Related]
10. Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments.
Manceau H; Gouya L; Puy H
Curr Opin Hematol; 2017 May; 24(3):198-207. PubMed ID: 28118224
[TBL] [Abstract][Full Text] [Related]
11. Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias.
Badawy AA
Med Hypotheses; 2019 Oct; 131():109314. PubMed ID: 31443750
[TBL] [Abstract][Full Text] [Related]
12. [Acute porphyrias viewed differently].
Barman-Aksözen J; Minder AE
Internist (Berl); 2022 Feb; 63(2):224-229. PubMed ID: 34762156
[TBL] [Abstract][Full Text] [Related]
13. Novel treatment options for acute hepatic porphyrias.
Wang B
Curr Opin Gastroenterol; 2021 May; 37(3):194-199. PubMed ID: 33769375
[TBL] [Abstract][Full Text] [Related]
14. Acute hepatic porphyrias: Recommendations for diagnosis and management with real-world examples.
Moghe A; Dickey A; Erwin A; Leaf RK; O'Brien A; Quigley JG; Thapar M; Anderson KE
Mol Genet Metab; 2023 Nov; 140(3):107670. PubMed ID: 37542766
[TBL] [Abstract][Full Text] [Related]
15. Acute Hepatic Porphyrias: "Purple Flags"-Clinical Features That Should Prompt Specific Diagnostic Testing.
Anderson KE; Desnick RJ; Stewart MF; Ventura P; Bonkovsky HL
Am J Med Sci; 2022 Jan; 363(1):1-10. PubMed ID: 34606756
[TBL] [Abstract][Full Text] [Related]
16. Acute hepatic porphyrias for the neurologist: current concepts and perspectives.
Souza PVS; Badia BML; Farias IB; Gonçalves EA; Pinto WBVR; Oliveira ASB
Arq Neuropsiquiatr; 2021 Jan; 79(1):68-80. PubMed ID: 33656101
[TBL] [Abstract][Full Text] [Related]
17. [Anesthesia in patients with acute porphyria].
Lederer D; Weigand MA; Larmann J
Anaesthesist; 2022 Apr; 71(4):321-330. PubMed ID: 35352131
[TBL] [Abstract][Full Text] [Related]
18. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.
Yasuda M; Chen B; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):320-331. PubMed ID: 30594473
[TBL] [Abstract][Full Text] [Related]
19. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
[TBL] [Abstract][Full Text] [Related]
20. Porphyric neuropathy.
Lin CS; Park SB; Krishnan AV
Handb Clin Neurol; 2013; 115():613-27. PubMed ID: 23931806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
